Evidence map›Paper›PMID 37599975›Full record

ArticleACS omega2023

Multifunctional Nanoscale Platform for the Study of T Cell Receptor Segregation.

Esti Toledo, Muhammed Iraqi, Ashish Pandey, Sivan Tzadka, Guillaume Le Saux, Angel Porgador, Mark Schvartzman

Abstract read
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Esti ToledoDepartment of Materials Engineering, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.ORCID https://orcid.org/0000-0003-3103-816X
Muhammed IraqiThe Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Science, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
Ashish PandeyDepartment of Materials Engineering, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
Sivan TzadkaDepartment of Materials Engineering, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
Guillaume Le SauxDepartment of Materials Engineering, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.ORCID https://orcid.org/0000-0003-4902-1980
Angel PorgadorThe Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Science, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.
Mark SchvartzmanDepartment of Materials Engineering, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.ORCID https://orcid.org/0000-0002-5912-525X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cells respond not only to biochemical stimuli transmitted through their activating, costimulatory, and inhibitory receptors but also to biophysical aspects of their environment, including the receptors' spatial arrangement. While these receptors form nanoclusters that can either colocalize or segregate, the roles of these colocalization and segregation remain unclear. Deciphering these roles requires a nanoscale platform with independent and simultaneous spatial control of multiple types of receptors. Herein, using a straightforward and modular fabrication process, we engineered a tunable nanoscale chip used as a platform for T cell stimulation, allowing spatial control over the clustering and segregation of activating, costimulatory, and inhibitory receptors. Using this platform, we showed that, upon blocked inhibition, cells became sensitive to changes in the nanoscale ligand configuration. The nanofabrication methodology described here opens a pathway to numerous studies, which will produce an important insight into the molecular mechanism of T cell activation. This insight is essential for the fundamental understanding of our immune system as well as for the rational design of future immunotherapies.

Identifiers

PMID37599975
PMCPMC10433356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.